Concepedia

James R. Falsey

JR

12

Publications

1.1K

Citations

12

H-Index

2001

Active since

Affiliations

Amgen (United States)(Current)

James R. Falsey is an author at Amgen (United States) specializing in drug development, drug discovery, and medicine.

Top concepts

Publications per year

2001–2024

12

Publications

12

Peptide and Small Molecule Microarray for High Throughput Cell Adhesion and Functional Assays

James R. Falsey, Manat Renil, Steven Park et al. · Bioconjugate Chemistry · 2001 · 324 citations

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

Murielle M. Véniant, Shu-Chen Lu, Larissa Atangan et al. · Nature Metabolism · 2024 · 160 citations · Full text

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

Elizabeth A. Killion, Michelle Chen, James R. Falsey et al. · Nature Communications · 2020 · 129 citations · Full text

Novel Vanilloid Receptor-1 Antagonists:  2. Structure−Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate

Elizabeth M. Doherty, Christopher Fotsch, Anthony W. Bannon et al. · Journal of Medicinal Chemistry · 2007 · 98 citations · Full text

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys

Shu-Chen Lu, Michelle Chen, Larissa Atangan et al. · Cell Reports Medicine · 2021 · 80 citations · Full text

Rows per page

1–5 of 12